8-K: bioAffinity Technologies Prices and Closes $3.25 Million Public Offering

bioAffinity Technologies successfully priced and closed a public offering, raising $3.25 million for working capital and general corporate purposes.

Summary

• bioAffinity Technologies, Inc. (BIAF) announced the pricing and subsequent closing of a public offering on May 7, 2025.
• The offering generated gross proceeds of approximately $3.25 million before deducting placement agent fees and other offering expenses.
• The offering included 7,784,904 shares of common stock and pre-funded warrants to purchase up to 2,371,346 shares.
• Accompanying warrants were issued to purchase up to 15,234,375 shares of common stock.
• Each share and accompanying warrant were sold at a combined price of $0.32, while each pre-funded warrant and accompanying warrant were sold at $0.313.
• The company intends to use the proceeds for working capital and other general corporate purposes.
• WallachBeth Capital LLC acted as the sole placement agent for the offering, receiving an 8% fee and $120,000 for expenses.
• The company agreed to issue warrants to the placement agent to purchase 304,687 shares of common stock, equal to 3% of the shares and pre-funded warrants sold in the offering.
• The pre-funded warrants are immediately exercisable at $0.007 per share and remain exercisable until fully exercised.
• The May 2025 warrants have an initial exercise price of $0.352 per share and expire five years after the stockholder approval notice date and the effective date of the Certificate of Amendment.
• The number of outstanding shares of Common Stock after the closing of the Offering and the exercise of certain Pre-Funded Warrants is 27,249,462.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The company successfully completed a financing, which is generally a positive event. However, there are potential dilution risks associated with the offering.

Positives

• The company successfully raised capital to fund working capital and general corporate purposes.
• The offering included a mix of common stock and warrants, potentially attracting a broader range of investors.
• The pre-funded warrants offer immediate exercisability at a low price, providing immediate capital to the company upon exercise.
• The company has the flexibility to use the proceeds for various corporate needs.

Negatives

• The offering involved the issuance of a significant number of new shares, which could dilute existing shareholders.
• The warrants issued in the offering could create future dilution if exercised.
• The company is restricted from certain equity issuances and variable rate transactions for a specified period.
• The May 2025 Warrants may be exercised on a cashless basis if at the time of exercise there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the May 2025 Warrant Shares to the holder.

Risks

• Future dilution from the exercise of warrants could negatively impact the stock price.
• Market conditions and investor sentiment could affect the company's ability to raise capital in the future.
• The company's reliance on a single product, CyPath Lung, exposes it to risks associated with its commercial success.
• The company's ability to achieve its business objectives depends on its ability to obtain regulatory approvals and successfully commercialize its products.
• The company may need to raise additional capital in the future, which may not be available on favorable terms or at all.
• The company agreed not to consummate a subsequent offering of its securities at a price less than the exercise price of the May 2025 Warrants immediately prior to such subsequent offering (a Dilutive Issuance) until the earlier of (i) eight months from the closing date of the Offering; and (ii) later of: (a) the filing of a registration statement registering certain shares of Common Stock issuable as a result of the Anti-Dilution Adjustment; (b) the Stockholder Approval Notice Date; and (c) the effective date of the filing of the Certificate of Amendment.

Future Outlook

The company intends to use the proceeds from the offering for working capital and other general corporate purposes.

Industry Context

The announcement reflects a common financing strategy for biotechnology companies, which often require significant capital to fund research, development, and commercialization efforts. The company's focus on noninvasive cancer diagnostics aligns with a growing trend in the healthcare industry towards early detection and personalized medicine.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector, such as Exact Sciences (EXAS) and Guardant Health (GH), also utilize public offerings to fund their operations and growth initiatives.
• The terms of the offering, including the size, pricing, and warrant coverage, are generally consistent with industry standards for similar-stage biotechnology companies.
• The use of a best-efforts placement agent is a common approach for smaller offerings, while larger offerings may involve underwritten deals with investment banks.
• The focus on working capital and general corporate purposes is a typical use of proceeds for such offerings, allowing companies to fund ongoing operations and strategic initiatives.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's employees and customers may benefit from the increased financial stability and resources.
• The company's suppliers and creditors may benefit from the company's ability to meet its obligations.

Next Steps

• The company will use the proceeds for working capital and general corporate purposes.
• The company will need to manage the potential dilution from the exercise of warrants.
• The company will need to comply with the restrictions on future equity issuances.
• The company will need to obtain stockholder approval for certain warrant adjustments and an increase in authorized shares.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, capital raise, bioAffinity Technologies, WallachBeth Capital, dilution, CyPath Lung, financing